<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35257202</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2366-0058</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Abdominal radiology (New York)</Title>
          <ISOAbbreviation>Abdom Radiol (NY)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pancreatic enlargement in a patient receiving therapy with vasodilators for pulmonary arterial hypertension: a case report.</ArticleTitle>
        <Pagination>
          <StartPage>1948</StartPage>
          <EndPage>1953</EndPage>
          <MedlinePgn>1948-1953</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00261-022-03458-9</ELocationID>
        <Abstract>
          <AbstractText>Epoprostenol is a prostacyclin (prostaglandin I2) analog that causes vasodilation and inhibits platelet aggregation and is used in the management of severe pulmonary arterial hypertension (PAH). We herein report a patient with PAH who developed pancreatic enlargement after the initiation of therapy including epoprostenol. Although it is well known that thyroid enlargement occurs in patients with PAH receiving epoprostenol therapy, the pancreatic findings associated with epoprostenol therapy have not been well described. Although the size of the pancreas was clearly increased, there was no blood data or symptoms suggestive of abnormal pancreatic function and pancreatitis, and the patient's abdominal complaints improved quickly, despite the continuation of epoprostenol therapy. Eleven months after the start of continuous intravenous epoprostenol infusion therapy, the pancreatic enlargement was still evident on imaging, but there were no abdominal symptoms or elevated pancreatic enzymes. This case highlights the fact that epoprostenol therapy may cause pancreatic changes that mimic acute or autoimmune pancreatitis.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Someya</LastName>
            <ForeName>Yuko</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-2985-761X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. someyayuko@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koyasu</LastName>
            <ForeName>Sho</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohnishi</LastName>
            <ForeName>Yasuyuki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohno</LastName>
            <ForeName>Tsuyoshi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Hironori</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Isoda</LastName>
            <ForeName>Hiroyoshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamoto</LastName>
            <ForeName>Yuji</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Abdom Radiol (NY)</MedlineTA>
        <NlmUniqueID>101674571</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DCR9Z582X0</RegistryNumber>
          <NameOfSubstance UI="D011464">Epoprostenol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011464" MajorTopicYN="N">Epoprostenol</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010179" MajorTopicYN="N">Pancreas</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081029" MajorTopicYN="Y">Pulmonary Arterial Hypertension</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Continuous intravenous prostacyclin analog infusion therapy</Keyword>
        <Keyword MajorTopicYN="N">Epoprostenol</Keyword>
        <Keyword MajorTopicYN="N">Pancreatic enlargement</Keyword>
        <Keyword MajorTopicYN="N">Pulmonary arterial hypertension</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35257202</ArticleId>
        <ArticleId IdType="doi">10.1007/s00261-022-03458-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00261-022-03458-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114:1417–1431</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.104.503540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prins KW, Thenappan T (2016) World health organization group I pulmonary hypertension: Epidemiology and pathophysiology. Cardiol Clin 34:363–374</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccl.2016.04.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galiè N, Humbert M, Vachiery J-L, et al (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 46:903–975</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.01032-2015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda K, Date H, Doi S, et al (2019) Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 83:842–945</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1253/circj.CJ-66-0158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barst RJ, Rubin LJ, Long WA, et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296–301</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199602013340504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chadha C, Pritzker M, Mariash CN (2009) Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. Endocr Pract 15:116–121</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP.15.2.116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satoh M, Aso K, Nakayama T, Saji T (2017) Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension. Endocr J 64:1173–1180</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1507/endocrj.EJ17-0155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon AA, Sahay S, Braverman LE, Farber HW (2019) Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway. Lung 197:761–768</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00408-019-00283-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saisho Y, Butler AE, Meier JJ, et al (2007) Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat 20:933–942</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ca.20543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirai Y, Tamura Y, Yasuoka H, et al (2014) IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment. Eur Respir J 43:1516–1519</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.00144013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majed BH, Khalil RA (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev 64:540–582</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pr.111.004770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beswick IP, Pirola RC, Bouchier IA (1971) The cause of pancreatic enlargement in rats fed raw soybean. Br J Exp Pathol 52:252–255</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5104540</ArticleId>
            <ArticleId IdType="pmc">2072329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato M, Ohkuma S, Kataoka K, et al (1994) Mechanisms for pancreatic hypertrophy induced by long-term administration of bethanechol. Eur J Pharmacol (Environ Toxicol Pharmacol Sect) 292:47–55</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0926-6917(94)90025-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Homma T, Malik KU (1982) Effect of prostaglandins on pancreatic circulation in anesthetized dogs. J Pharmacol Exp Ther 222:623–628</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7050343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolenšek J, Pohorec V, Rupnik MS, Stožer A (2017) Pancreas Physiology. In: Seicean A (ed) Challenges in Pancreatic Pathology. IntechOpen, Rijeka</Citation>
        </Reference>
        <Reference>
          <Citation>Glasbrenner B, Adler G (1993) Pathophysiology of acute pancreatitis. Hepatogastroenterology 40:517–521</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8119636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X-M, Feng Z-S, Zhao Q-H, et al (2006) Acute interstitial edematous pancreatitis: Findings on non-enhanced MR imaging. World J Gastroenterol 12:5859–5865</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v12.i36.5859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Notohara Kenji ZL (2013) Histology of autoimmune pancreatitis. The Pancreapedia: Exocrine Pancreas Knowledge Base</Citation>
        </Reference>
        <Reference>
          <Citation>Takahashi M, Fujinaga Y, Notohara K, et al (2020) Diagnostic imaging guide for autoimmune pancreatitis. Jpn J Radiol 38:591–612</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11604-020-00971-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T, Takuma K, Anjiki H, et al (2010) Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. Am J Gastroenterol 105:1870–1875</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2010.87</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
